BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 3,410 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 3,410 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $273.78, for a total value of $933,589.80. Following the transaction, the chief executive officer owned 1,610 shares of the company’s stock, valued at approximately $440,785.80. The trade was a 67.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Oyler also recently made the following trade(s):

• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total value of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The shares were sold at an average price of $257.24, for a total value of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total transaction of $1,336,566.40.

BeOne Medicines Stock Down 0.6%

BeOne Medicines stock opened at $275.34 on Friday. The company has a 50-day simple moving average of $292.55 and a 200-day simple moving average of $310.42. The firm has a market capitalization of $30.21 billion, a P/E ratio of 61.60 and a beta of 0.49. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.27 and a current ratio of 3.64. BeOne Medicines Ltd. – Sponsored ADR has a one year low of $239.25 and a one year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $1.51 billion for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. As a group, equities analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Hedge Funds Weigh In On BeOne Medicines

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. EFG International AG bought a new position in BeOne Medicines during the fourth quarter valued at about $25,000. Leonteq Securities AG bought a new stake in shares of BeOne Medicines in the 4th quarter worth approximately $35,000. Daiwa Securities Group Inc. acquired a new stake in BeOne Medicines during the second quarter valued at approximately $35,000. CWM LLC lifted its position in shares of BeOne Medicines by 32.8% during the 4th quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after acquiring an additional 39 shares during the last quarter. Finally, Group One Trading LLC purchased a new stake in shares of BeOne Medicines during the fourth quarter valued at $61,000. 48.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ONC. Wolfe Research began coverage on BeOne Medicines in a research report on Friday, March 27th. They set an “outperform” rating and a $340.00 price objective for the company. Wall Street Zen downgraded BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 20th. Guggenheim boosted their price target on BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Jefferies Financial Group cut BeOne Medicines from a “buy” rating to a “hold” rating and decreased their price target for the stock from $420.00 to $290.00 in a research note on Monday, March 16th. Finally, Royal Bank Of Canada raised their price target on BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $390.00.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.